source
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.BioPharma Dive · 2mo ago↗ source
- The Type of Fat—Not the Amount—Fuels Pancreatic CancerResearch from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.onclive · 2mo ago↗ source
- Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83MA blood test might predict who will respond to Wegovy; Viridian's thyroid eye disease drug wins another Phase 3; Ideaya drops two GSK-returned assets. 🧬 Second life for a gene therapy: A Cleveland…Endpoints